The purpose of this clinical research study is to learn if BMS-247550 added to the approved therapy of capecitabine (Xeloda) provides measurable clinical benefits over capecitabine alone in women with metastatic breast cancer. Patients should have previously received an anthracycline and a taxane. The safety of this treatment will also be studied.
Ixabepilone lypholized powder/Diluent for solution for injection/Tablets, IV/Oral, 40 mg/m2 + Capecitabine 2000 mg/m2, Ixabepilone on Day 1 and Capecitabine twice daily Days 1-14 of 21 day cycle
Tablet, Oral, 2500 mg/m2, Capecitabine twice daily Days 1-14 of 21 day cycle
Avellaneda, Buenos Aires, Argentina
Bahía Blanca, Buenos Aires, Argentina
Belén de Escobar, Buenos Aires, Argentina
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
Resistencia, Chaco Province, Argentina
Barrio Alto Verde, Córdoba Province, Argentina
San Miguel de Tucumán, Tucumán Province, Argentina
Buenos Aires, Argentina
Mendoza, Argentina
Salta, Argentina
Santa Fe, Argentina